Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution

The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

Inclusion Criteria:

• 18 years or older.
• Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as specified in protocol.
• Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.
• Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATAN®) for at least one continuous month prior to Visit 1.
• Willing and able to discontinue use of any topical ocular medicine other than the study medication for the duration of the study, including artificial tears.
• Best corrected visual acuity of -0.6 logMAR or better in each eye.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Any medical condition (systemic or ophthalmic) that may preclude safe administration of the test article.
• Use of contact lenses within 30 days of Visit 1.
• Use of contact lenses during the study.
• Participation in an investigational drug or device study within 30 days of entering this study.
• Other protocol-defined exclusion criteria may apply.